# Palisade Bio, Inc.: financial statements, quarterly

PALI · Nasdaq · CIK 1357459 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pali.md) · [Financials](/companies/pali/financials.md) · [Filings](/companies/pali/filings.md) · [Insiders](/companies/pali/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pali/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-124664.md) | [0.0 d](/filings/0000950170-25-043859.md) | [0.0](/filings/0000950170-24-058644.md) | [0.0](/filings/0000950170-24-095432.md) | [0.0](/filings/0000950170-24-124664.md) | [0.0 d](/filings/0000950170-25-043859.md) | [0.0](/filings/0001357459-26-000010.md) | [0.0](/filings/0001357459-26-000016.md) | [0.0](/filings/0001193125-25-274262.md) | [0.0 d](/filings/0001357459-26-000004.md) | [0.0](/filings/0001357459-26-000010.md) | [0.5](/filings/0001357459-26-000016.md) |
| Research and development | $m | not reported | [0.4](/filings/0000950170-24-124664.md) | not reported | not reported | [16.0](/filings/0001193125-25-274262.md) | [0.0 d](/filings/0001357459-26-000004.md) | not reported | not reported | not reported | not reported | [6.0](/filings/0001357459-26-000010.md) | [6.0](/filings/0001357459-26-000016.md) |
| Operating income | $m | [(3.8)](/filings/0000950170-24-124664.md) | [(3.2) d](/filings/0000950170-25-043859.md) | [(3.7)](/filings/0000950170-25-069204.md) | [(4.2)](/filings/0000950170-25-106587.md) | [(3.6)](/filings/0001193125-25-274262.md) | [(3.4) d](/filings/0001357459-26-000004.md) | [(2.3)](/filings/0001357459-26-000010.md) | [(2.8)](/filings/0001357459-26-000016.md) | [(2.9)](/filings/0001193125-25-274262.md) | [(10.0) d](/filings/0001357459-26-000004.md) | [(10.7)](/filings/0001357459-26-000010.md) | [(11.7)](/filings/0001357459-26-000016.md) |
| Interest expense | $m | [0.0](/filings/0000950170-24-124664.md) | [0.0 d](/filings/0000950170-25-043859.md) | [0.0](/filings/0000950170-25-069204.md) | [0.0](/filings/0000950170-25-106587.md) | [0.0](/filings/0001193125-25-274262.md) | [0.0 d](/filings/0000950170-25-043859.md) | [0.0](/filings/0000950170-25-069204.md) | [0.0](/filings/0000950170-25-106587.md) | [0.0](/filings/0001193125-25-274262.md) | [0.0 d](/filings/0001357459-26-000004.md) | [0.0](/filings/0001357459-26-000010.md) | [0.0](/filings/0001357459-26-000016.md) |
| Net income | $m | [(3.6)](/filings/0000950170-24-124664.md) | [(3.0) d](/filings/0000950170-25-043859.md) | [(3.5)](/filings/0000950170-25-069204.md) | [(4.1)](/filings/0000950170-25-106587.md) | [(3.5)](/filings/0001193125-25-274262.md) | [(3.3) d](/filings/0001357459-26-000004.md) | [(2.2)](/filings/0001357459-26-000010.md) | [(2.8)](/filings/0001357459-26-000016.md) | [(2.9)](/filings/0001193125-25-274262.md) | [(8.9) d](/filings/0001357459-26-000004.md) | [(9.6)](/filings/0001357459-26-000010.md) | [(10.6)](/filings/0001357459-26-000016.md) |
| Diluted EPS | $ per share | [(7.38)](/filings/0000950170-24-124664.md) | not reported | [(4.59)](/filings/0000950170-25-069204.md) | [(3.32)](/filings/0000950170-25-106587.md) | [(2.32)](/filings/0001193125-25-274262.md) | not reported | [(0.47)](/filings/0001357459-26-000010.md) | [(0.58)](/filings/0001357459-26-000016.md) | [(0.38)](/filings/0001193125-25-274262.md) | not reported | [(0.05)](/filings/0001357459-26-000010.md) | [(0.05)](/filings/0001357459-26-000016.md) |
| Basic EPS | $ per share | [(7.38)](/filings/0000950170-24-124664.md) | not reported | [(4.59)](/filings/0000950170-25-069204.md) | [(3.32)](/filings/0000950170-25-106587.md) | [(2.32)](/filings/0001193125-25-274262.md) | not reported | [(0.47)](/filings/0001357459-26-000010.md) | [(0.58)](/filings/0001357459-26-000016.md) | [(0.38)](/filings/0001193125-25-274262.md) | not reported | [(0.05)](/filings/0001357459-26-000010.md) | [(0.05)](/filings/0001357459-26-000016.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [15.3](/filings/0000950170-24-124664.md) | [12.4](/filings/0000950170-25-043859.md) | [11.3](/filings/0000950170-25-069204.md) | [11.4](/filings/0000950170-25-106587.md) | [8.0](/filings/0001193125-25-274262.md) | [9.8](/filings/0001357459-26-000004.md) | [7.2](/filings/0001357459-26-000010.md) | [5.4](/filings/0001357459-26-000016.md) | [5.2](/filings/0001193125-25-274262.md) | [133](/filings/0001357459-26-000016.md) | [133](/filings/0001357459-26-000010.md) | [125](/filings/0001357459-26-000016.md) |
| Current assets | $m | [16.3](/filings/0000950170-23-062215.md) | [13.3](/filings/0000950170-25-043859.md) | [12.0](/filings/0000950170-24-058644.md) | [12.3](/filings/0000950170-24-095432.md) | [8.9](/filings/0000950170-24-124664.md) | [10.5](/filings/0001357459-26-000004.md) | [7.9](/filings/0000950170-25-069204.md) | [6.4](/filings/0000950170-25-106587.md) | [6.8](/filings/0001193125-25-274262.md) | [134](/filings/0001357459-26-000016.md) | [133](/filings/0001357459-26-000010.md) | [127](/filings/0001357459-26-000016.md) |
| Total assets | $m | [17.1](/filings/0000950170-23-062215.md) | [14.1](/filings/0000950170-25-043859.md) | [12.7](/filings/0000950170-24-058644.md) | [12.9](/filings/0000950170-24-095432.md) | [9.3](/filings/0000950170-24-124664.md) | [10.9](/filings/0001357459-26-000004.md) | [8.2](/filings/0000950170-25-069204.md) | [6.7](/filings/0000950170-25-106587.md) | [7.0](/filings/0001193125-25-274262.md) | [134](/filings/0001357459-26-000016.md) | [133](/filings/0001357459-26-000010.md) | [127](/filings/0001357459-26-000016.md) |
| Current liabilities | $m | [2.6](/filings/0000950170-23-062215.md) | [2.6](/filings/0000950170-25-043859.md) | [2.5](/filings/0000950170-24-058644.md) | [2.8](/filings/0000950170-24-095432.md) | [2.7](/filings/0000950170-24-124664.md) | [3.2](/filings/0001357459-26-000004.md) | [2.8](/filings/0000950170-25-069204.md) | [4.0](/filings/0000950170-25-106587.md) | [3.5](/filings/0001193125-25-274262.md) | [4.6](/filings/0001357459-26-000016.md) | [5.6](/filings/0001357459-26-000010.md) | [5.2](/filings/0001357459-26-000016.md) |
| Total liabilities | $m | [3.0](/filings/0000950170-23-062215.md) | [2.7](/filings/0000950170-25-043859.md) | [2.6](/filings/0000950170-24-058644.md) | [2.9](/filings/0000950170-24-095432.md) | [2.7](/filings/0000950170-24-124664.md) | [3.4](/filings/0001357459-26-000004.md) | [2.9](/filings/0000950170-25-069204.md) | [4.0](/filings/0000950170-25-106587.md) | [3.8](/filings/0001193125-25-274262.md) | [5.0](/filings/0001357459-26-000016.md) | [6.0](/filings/0001357459-26-000010.md) | [5.6](/filings/0001357459-26-000016.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [14.1](/filings/0000950170-24-124664.md) | [11.3](/filings/0001357459-26-000004.md) | [10.1](/filings/0000950170-25-106587.md) | [9.9](/filings/0001193125-25-274262.md) | [6.6](/filings/0001193125-25-274262.md) | [7.5](/filings/0001357459-26-000016.md) | [5.3](/filings/0001357459-26-000016.md) | [2.6](/filings/0001357459-26-000016.md) | [3.2](/filings/0001193125-25-274262.md) | [129](/filings/0001357459-26-000016.md) | [127](/filings/0001357459-26-000016.md) | [122](/filings/0001357459-26-000016.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,662) d](/filings/0000950170-24-124664.md) | [(2,746) d](/filings/0000950170-25-043859.md) | [(3,180)](/filings/0000950170-25-069204.md) | [(3,499) d](/filings/0000950170-25-106587.md) | [(3,133) d](/filings/0001193125-25-274262.md) | [(2,381) d](/filings/0001357459-26-000004.md) | [(2,333)](/filings/0001357459-26-000010.md) | [(1,817) d](/filings/0001357459-26-000016.md) | [(3,553) d](/filings/0001193125-25-274262.md) | [(3,144) d](/filings/0001357459-26-000004.md) | [(3,890)](/filings/0001357459-26-000010.md) | [(7,603) d](/filings/0001357459-26-000016.md) |
| Capital expenditure | $k | [0.0 d](/filings/0000950170-24-124664.md) | [0.0 d](/filings/0000950170-25-043859.md) | not reported | not reported | [0.0 d](/filings/0000950170-24-124664.md) | [0.0 d](/filings/0000950170-25-043859.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.0](/filings/0000950170-23-062215.md) | [0.3](/filings/0000950170-24-058644.md) | [0.4](/filings/0000950170-24-095432.md) | [0.5](/filings/0000950170-24-124664.md) | [0.8](/filings/0000950170-25-069204.md) | [1.2](/filings/0000950170-25-106587.md) | [1.5](/filings/0001193125-25-274262.md) | [4.8](/filings/0001357459-26-000010.md) | [4.8](/filings/0001357459-26-000016.md) | [7.5](/filings/0001193125-25-274262.md) | [210](/filings/0001357459-26-000010.md) | [211](/filings/0001357459-26-000016.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 174,270,558 at 2026-08-06, from the cover of the [10-Q filed 2026-08-10](/filings/0001357459-26-000016.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.